6533b872fe1ef96bd12d2dd5
RESEARCH PRODUCT
The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis.
Massimiliano AlùLivio BlasiAlessandro RussoTindara FranchinaAntonio RussoClaudia CelesiaGiovanni SortinoVincenzo AdamoAgata LaudaniGiuseppe BronteSergio RizzoFrancesco PassigliaAntonio PiconeGiuseppina Saviosubject
Cancer Researchmedicine.drug_classbusiness.industryWild typePharmacologymedicine.diseaseTyrosine-kinase inhibitorThird generationSecond lineOncologymedicineCancer researchRetrospective analysisNon small cellLung cancerbusinessTyrosine kinasedescription
e19030 Background: Second-line treatment for advanced non-small-cell lung cancer (aNSCLC) patients includes monotherapy with a third generation cytotoxic drug (CT) or with the tyrosine kinase inhib...
year | journal | country | edition | language |
---|---|---|---|---|
2015-05-20 | Journal of Clinical Oncology |